the joint commission developed this pain as the 5th vital sign. as part of a grant to that was provided to them by the pharmaceutical company purdue pharma the joint commission on accreditation of health care organizations recently defined and adopted stringent pain standards on the basic thrust of our new standards is the organizations that practitioners have an obligation to ask the patient even if the patient doesn't look like he or she is in pain ask them to be surprised but here when you go to a doctor's office now they ask you or are you having pain. no you may go for a raise that has nothing to do with pain which just added lighter fluid to the fire because because it became equivalent to say if you have pain you need opioids. at least in the united states you know 2 plus. you know probably not for making people smile and on oxy contemn produce marketing of oxycontin depending on how you look at it very successful very tragic all the marketing legislative maneuvering cash and free giveaways handed to doctors and politicians might have been justified if opioids were a safe effective non-addictive treatment for chronic pain but they weren't m

and according to a wall street journal article the joint commission published a guide sponsored by purdue pharma on pain management. and with those exaggerated concerns and those related to the use of oxycontin and said there was no evidence of addiction. and pain so what i would like to know for mr. landau, did purdue pharma find that research by the joint commission? >> with respect, i don't know. i said in an earlier testimony before becoming ceo i was entrenched in research and development and that is an area outside of my area of responsibility i get back to you certainly after the hearing with that information. >> mr. sackler did you find any of the research from the joint commission? >> i simply don't know. >> the answer to the question is yes. >> your company mounted an aggressive marketing campaign that the fda warned that was misleading. are you aware of that? >> my recollection is that the fda warning letter in 2003 was related to a single ad in a journal article. . . . . but yod i think in a dishonest way pushed this drug on doctors and it ramped up after the changes in the affordabl